Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations. 

‘We’ve got these enormous markets,’ Rob Califf says. ‘Should 65% of the US population be treated with obesity drugs?’

Large employer plan sponsors split on whether to cover GLP-1 drugs for weight loss, according to a recent survey.

From when the consent process starts to how to handle standard of care discussions, US FDA’s long-awaited final guidance on informed consent reflects some changes sought by sponsors. More changes may be in store soon due to revisions of the Common Rule.